Holen Sie sich die Stockscreener-App
55.07
0.07%
0.04
Vorhandelsmarkt:
55.07
Schlusskurs vom Vortag:
$55.03
Offen:
$55.44
24-Stunden-Volumen:
386.71K
Relative Volume:
0.76
Marktkapitalisierung:
$3.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-23.94
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
+3.73%
1M Leistung:
+16.26%
6M Leistung:
+20.50%
1J Leistung:
+22.62%
1-Tages-Spanne:
$54.36
$55.72
1-Wochen-Bereich:
$52.65
$57.45
52-Wochen-Spanne:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
55.07 | 3.49B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
How does MoonLake Immunotherapeutics compare to its industry peersInvest smarter with advanced market data - jammulinksnews.com
Is MoonLake Immunotherapeutics stock overvalued or undervaluedTake advantage of unprecedented market momentum - jammulinksnews.com
How does MoonLake Immunotherapeutics generate profit in a changing economyMaximize your gains with expert trading tips - jammulinksnews.com
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Invest confidently with professional advice - jammulinksnews.com
Does MoonLake Immunotherapeutics stock perform well during market downturnsStrong return on assets - jammulinksnews.com
How strong is MoonLake Immunotherapeutics company’s balance sheetCapitalize on emerging market sectors - jammulinksnews.com
What are MoonLake Immunotherapeutics company’s key revenue driversBuild a diversified portfolio for stability - jammulinksnews.com
Does MoonLake Immunotherapeutics (NASDAQ:MLTX) Have A Healthy Balance Sheet? - 富途牛牛
What analysts say about MoonLake Immunotherapeutics stockMarket-leading profit generation - Autocar Professional
MoonLake Immunotherapeutics Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
Is MoonLake Immunotherapeutics a good long term investmentBreakthrough stock performance - jammulinksnews.com
Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com
MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks
What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com
(MLTX) Trading Advice - news.stocktradersdaily.com
MoonLake Immunotherap Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
What makes MoonLake Immunotherapeutics stock price move sharplyFree Investment Risk Control - Newser
Why MoonLake Immunotherapeutics stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser
How MoonLake Immunotherapeutics stock performs during market volatilityQuick Profit Idea Stream - Newser
MoonLake Immunotherap Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
MoonLake Immunotherap Getting Closer To Key Technical Benchmark - Investor's Business Daily
MoonLake Immunotherapeutics Director Makes a Major Stock Move! - TipRanks
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Sector Challenges - geneonline.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com
Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):